Suven Life Sciences acquires patents to treat neurodegenerative diseases

To treat disorders associated with neurodegenerative diseases, Suven Life Sciences has secured process patents from Europe, Japan, and New Zealand. These patents are for New Chemical Entities (NCEs) and valid through 2034.
 
The patents will be of use for the company’s pipeline compounds in the selective 5HT6 category and will be developed as therapeutic agents useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s, Attention Deficient Hyperactivity Disorder (ADHD), Huntington’s Disease, Parkinson and schizophrenia.
 
Meanwhile, the stock was trading higher by 5.14% at Rs 165 per share on the BSE at 1053 hours. It opened at Rs 157.55 per share and touched its intraday high and low at Rs 167.10 and Rs 157.55 per share respectively. It attracted total traded volume of 4,07,898 shares and traded value of Rs 670.95 lakhs on the NSE at 1055.